Top Research Reports for NVIDIA, Amazon.com & UnitedHealth
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be. -- Barrons.com
By Jacob Sonenshine Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of new GLP-1 developments. It's an overreaction -- and the stock is a buy. Shares ar
Thermo Fisher's (TMO) New Launch Speeds Up PDNA Purification
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
U.S. Home Durable Medical Equipment Market Analysis Report 2024-2030 Featuring Compass Health Brands, Invacare, Rotech Healthcare, Medline Industries, Masimo, and ResMed
Oppenheimer Downgrades ResMed(RMD.US) to Hold Rating
Oppenheimer analyst Suraj Kalia downgrades $ResMed(RMD.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 51.9% and a total average return of 7.0% over the past year.N
ResMed Shares Hit as Eli Lilly's Weight Loss Drug Demonstrates Sleep Apnoea Benefits
ResMed Cut at Oppenheimer After Eli Lilly's Tirzepatide Sleep Apnea Data
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Analysts' ratings for ResMed (NYSE:RMD) over the last quarter vary from bullish to bearish, as provided by 6 analysts.The table below provides a concise overview of recent ratings by analysts, offerin
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $225 to $236
On Jun 25, major Wall Street analysts update their ratings for $ResMed(RMD.US)$, with price targets ranging from $225 to $236.BofA Securities analyst Lyanne Harrison maintains with a buy rating, and m
Express News | Resmed : Oppenheimer Cuts to Perform From Outperform
Oppenheimer Downgrades ResMed to Market Perform From Outperform
ResMed (RMD) has an average outperform rating and a price target range of $21.64 to $264, according to analysts polled by Capital IQ. Price: 210.00, Change: -1.66, Percent Change: -0.78
ResMed Loses Bull Amid Weight-Loss Drug Concerns -- Market Talk
0222 GMT - ResMed loses its bull at Citi amid concerns about the impact of weight-loss drugs and the resurgence of one of the breathing-tech provider's main rivals. Analyst Mathieu Chevrier tells clie
Top Gap Ups and Downs on Monday: TSM, QCOM, SNY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
US stocks closing | S&P continued to fall! AI stocks cooled down again, with Nvidia falling nearly 7%, market cap falling below $3 trillion.
The Dow Jones Industrial Average rose for the fifth consecutive day to a five-week high. The Chinese concept stock index outperformed, closing up 1.3%. NIO Inc and Li Auto Inc rose more than 3%, while Xpeng rose more than 2%.
ResMed Cut to Neutral From Buy by Citigroup >RMD.AU
ResMed Cut to Neutral From Buy by Citigroup >RMD.AU
ResMed Target Price Cut 17% to A$30.00/Share by Citi>RMD.AU
ResMed Target Price Cut 17% to A$30.00/Share by Citi>RMD.AU
How Lilly Is Joining Novo in the Crusade to Circumvent Medicare's Block on Weight Loss Drugs
Medicare is the largest individual insurance payer of health costs in the country.